JP7179353B2 - γ－ケトアルデヒドスカベンジャーによる心房細動／粗動の予防及び治療 - Google Patents

γ－ケトアルデヒドスカベンジャーによる心房細動／粗動の予防及び治療 Download PDF

Info

Publication number
JP7179353B2
JP7179353B2 JP2019500259A JP2019500259A JP7179353B2 JP 7179353 B2 JP7179353 B2 JP 7179353B2 JP 2019500259 A JP2019500259 A JP 2019500259A JP 2019500259 A JP2019500259 A JP 2019500259A JP 7179353 B2 JP7179353 B2 JP 7179353B2
Authority
JP
Japan
Prior art keywords
atrial
isolg
atrial fibrillation
anp
pao
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019500259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520389A5 (enExample
JP2019520389A (ja
Inventor
ティー． マリー，キャサリン
セカンド ロバーツ，エル．ジャクソン
アマーナス，ベンカタラマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2019520389A publication Critical patent/JP2019520389A/ja
Publication of JP2019520389A5 publication Critical patent/JP2019520389A5/ja
Application granted granted Critical
Publication of JP7179353B2 publication Critical patent/JP7179353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2019500259A 2016-07-07 2017-07-07 γ－ケトアルデヒドスカベンジャーによる心房細動／粗動の予防及び治療 Active JP7179353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359705P 2016-07-07 2016-07-07
US62/359,705 2016-07-07
PCT/US2017/041211 WO2018009875A1 (en) 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Publications (3)

Publication Number Publication Date
JP2019520389A JP2019520389A (ja) 2019-07-18
JP2019520389A5 JP2019520389A5 (enExample) 2020-08-06
JP7179353B2 true JP7179353B2 (ja) 2022-11-29

Family

ID=60913210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500259A Active JP7179353B2 (ja) 2016-07-07 2017-07-07 γ－ケトアルデヒドスカベンジャーによる心房細動／粗動の予防及び治療

Country Status (10)

Country Link
US (2) US20190247375A1 (enExample)
EP (1) EP3481505B1 (enExample)
JP (1) JP7179353B2 (enExample)
CN (1) CN110022936A (enExample)
AU (1) AU2017293950B2 (enExample)
BR (1) BR112019000251A2 (enExample)
CA (1) CA3030149A1 (enExample)
ES (1) ES3040735T3 (enExample)
MX (1) MX393913B (enExample)
WO (1) WO2018009875A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249562A1 (en) 2006-04-25 2007-10-25 Friesen Albert D Treatment of atrial fibrillation
US20120157501A1 (en) 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620836B1 (en) * 1997-01-22 2003-09-16 Jay Patrick Antiarrhythmic and tranquilizer composition and treatment
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
PL2731597T3 (pl) * 2011-07-12 2024-04-29 Vanderbilt University Sposoby leczenia stanu zapalnego i nadciśnienia tętniczego za pomocą wychwytywaczy gamma-ketoaldehydowych

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157501A1 (en) 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US20070249562A1 (en) 2006-04-25 2007-10-25 Friesen Albert D Treatment of atrial fibrillation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Molecular and Cellular Cardiology，2015年，79，pp.295-302

Also Published As

Publication number Publication date
CN110022936A (zh) 2019-07-16
AU2017293950B2 (en) 2023-06-15
AU2017293950A1 (en) 2019-01-31
MX2019000120A (es) 2019-04-01
US20240189291A1 (en) 2024-06-13
EP3481505C0 (en) 2025-09-03
BR112019000251A2 (pt) 2019-04-16
EP3481505B1 (en) 2025-09-03
US20190247375A1 (en) 2019-08-15
EP3481505A1 (en) 2019-05-15
JP2019520389A (ja) 2019-07-18
EP3481505A4 (en) 2020-02-26
MX393913B (es) 2025-03-24
CA3030149A1 (en) 2018-01-11
WO2018009875A1 (en) 2018-01-11
ES3040735T3 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
Wang et al. Homocysteine induces mitochondrial dysfunction and oxidative stress in myocardial ischemia/reperfusion injury through stimulating ROS production and the ERK1/2 signaling pathway
Joshi et al. Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease
Joshi et al. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease
O’Sullivan et al. Renal aging: causes and consequences
Zeng et al. Neurotrophins enhance CaMKII activity and rescue amyloid-β-induced deficits in hippocampal synaptic plasticity
EP3019591B1 (en) Neurodegenerative disorders
Ferguson et al. Non-sirtuin histone deacetylases in the control of cardiac aging
US10092627B2 (en) Methods and compositions for rejuvenating skeletal muscle stem cells
Palhegyi et al. Biomedical implications of autophagy in macromolecule storage disorders
C Correia et al. Defective HIF signaling pathway and brain response to hypoxia in neurodegenerative diseases: not an “iffy” question!
Kelliny et al. A new approach to model sporadic Alzheimer’s disease by intracerebroventricular streptozotocin injection in APP/PS1 mice
Kozin et al. The convergence of Alzheimer’s disease pathogenesis concepts
Su et al. Metabolic control of the proteotoxic stress response: implications in diabetes mellitus and neurodegenerative disorders
Dinamarca et al. Release of acetylcholinesterase (AChE) from β-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice
US20160339055A1 (en) Lithium co-crystals for treatment of neuropsychiatric disorders
JP2023055890A (ja) 加齢性疾患及び／又は変性疾患に使用される医薬配合剤
Lopez et al. Enhancing endogenous nitric oxide by whole body periodic acceleration elicits neuroprotective effects in dystrophic neurons
Palomo et al. The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy
US10022341B2 (en) Methods of preventing neurodegeneration of association cortex in a mammal
JP7179353B2 (ja) γ－ケトアルデヒドスカベンジャーによる心房細動／粗動の予防及び治療
US20220265635A1 (en) Treatment of neurological disease
KR20180007307A (ko) 자가포식 향상물질 및 그 용도
Zhang et al. Protective effect of S14G-humanin against beta-amyloid induced LTP inhibition in mouse hippocampal slices
Sakuma et al. Molecular mechanisms controlling skeletal muscle mass
Lu et al. Protective effect of olmesartan against cardiac ischemia/reperfusion injury in spontaneously hypertensive rats

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221109

R150 Certificate of patent or registration of utility model

Ref document number: 7179353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250